07:10 AM EST, 11/12/2024 (MT Newswires) -- Springworks Therapeutics ( SWTX ) reported a Q3 net loss Tuesday of $0.72 per diluted share, narrowing from the $1.27 loss a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.76 per share.

Revenue for the quarter ended Sept. 30 was $49.3 million. No revenue was reported a year earlier.

Analysts polled by Capital IQ expected $55.1 million.

The company said it had $498.1 million in cash, cash equivalents and marketable securities as of Sept. 30, expected to fund its operations through H1 2026.

Shares of Springworks Therapeutics ( SWTX ) were down more than 11% in recent premarket activity.